Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Biodexa Pharmaceuticals PLC BDRX

Healthcare Biotechnology
Biodexa Pharmaceuticals PLC is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is developing a pipeline of products for the treatment of diseases with unmet medical needs. Its technologies include Biodexa Pharmaceuticals Q-Sphera, MidaCore and MidaSolve. The Q-Sphera technology focuses on long-acting injectables using proprietary three-dimensional (3D) printing... see more

Recent & Breaking News (NDAQ:BDRX)

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biodexa Pharmaceuticals Plc - BDRX

PR Newswire October 17, 2024

Biodexa's MX-110 Continues to Show Promise in Recurrent Glioblastoma (rGBM), the Deadliest Brain Cancer

Accesswire October 17, 2024

Shareholders that lost money on Biodexa Pharmaceuticals Plc(BDRX) should contact Levi & Korsinsky about Securities Fraud Investigation - BDRX

Accesswire October 16, 2024

Bronstein, Gewirtz & Grossman, LLC Is Investigating Biodexa Pharmaceuticals Plc (BDRX) And Encourages Stockholders to Connect

Accesswire October 16, 2024

Lost Money on Biodexa Pharmaceuticals Plc (BDRX)? Contact Levi & Korsinsky Regarding an Ongoing Investigation

Accesswire October 16, 2024

Biodexa Announces Successful Appeal of Nasdaq Delisting

GlobeNewswire October 15, 2024

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biodexa Pharmaceuticals Plc - BDRX

Accesswire October 15, 2024

Biodexa Provides Update on Progression Free and Overall Survival in Phase 1 Study of MTX110 in Recurrent Glioblastoma

GlobeNewswire October 4, 2024

Interim results for the six months ended June 30, 2024

GlobeNewswire September 26, 2024

ADR Ratio Change

GlobeNewswire September 19, 2024

Announces Payment of $3.0MM Final Match Payment Enabling Access to Remainder of $17.0MM CPRIT Grant

GlobeNewswire September 16, 2024

Receipt of Nasdaq Delisting Determination - Plans to Appeal

GlobeNewswire August 30, 2024

Announces Closing of $5.0 Million Registered Direct Offering and Concurrent Private Placement

GlobeNewswire July 23, 2024

Announces Pricing of $5.0 Million Registered Direct Offering and Concurrent Private Placement

GlobeNewswire July 19, 2024

Biodexa Announces Phase 2a Study of Tolimidone in Type 1 Diabetes Approved by Health Canada

GlobeNewswire July 16, 2024

Biodexa Announces Additional Positive Results Of Phase 2 Trial Of eRapa in Treatment Of Precancerous Polyps in the GI Tract - Now 12-Month Data

Accesswire July 11, 2024

Positive Phase 1 Clinical Data of MTX110 in DMG Brain Cancer Demonstrating Increased Survival Presented at ISPNO 2024

GlobeNewswire July 2, 2024

Biodexa Announces Positive Phase 2 Clinical Trial Results of eRapa(TM) at 12 months in Familial Adenomatous Polyposis (FAP)

GlobeNewswire June 24, 2024

Results of Annual General Meeting

GlobeNewswire June 13, 2024

Twelve month Phase 2 Clinical Trial Results of eRapa(TM) in Familial Adenomatous Polyposis (FAP) to be Presented at Prestigious Biennial InSIGHT 2024 Meeting in Barcelona

GlobeNewswire June 10, 2024